Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| FOLD | AMICUS THERAPEUTICS, INC. | 2025-10-30 17:44:33 | 8.88 | -0.02 | -0.22 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FOLD | 0001178879 | AMICUS THERAPEUTICS, INC. | US03152W1099 | 549300MRD1SMUTNBPQ53 | 200422823 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 47 HULFISH STREET | PRINCETON | NJ | 08542 | UNITED STATES | US | (609) 662-2000 | 47 HULFISH STREET, PRINCETON, NJ, 08542 | 47 HULFISH STREET, PRINCETON, NJ, 08542 | AMICUS THERAPEUTICS INC | Biotechnology | 2002-02-04 | — | 508 | https://www.amicusrx.com/ | 2,940,574,460 | 308,064,329 | 308,239,374 | Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates. | 2025-10-30 13:53:22 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 2,940,574,460 | -616,374,057 | -17.3287 | 300,116,081 | 4,733,467 | 1.6025 |
| 2023 | 3,556,948,517 | 577,125,131 | 19.3678 | 295,382,614 | 12,667,876 | 4.4808 |
| 2022 | 2,979,823,386 | 439,207,797 | 17.2875 | 282,714,738 | 2,685,393 | 0.959 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Ellen S. Rosenberg | Chief Legal Officer, Corporate Secretary | 2024 | 514,423 | 332,886 | 2,048,280 | — | 40,475 | 3,800,307 |
| David M. Clark | Chief People Officer | 2024 | 482,903 | 270,197 | 1,564,136 | — | 38,006 | 3,015,209 |
| Bradley L. Campbell | Chief Executive Officer, President | 2024 | 767,308 | 623,700 | 4,990,365 | — | 39,943 | 8,526,943 |
| Simon Harford | Chief Financial Officer | 2024 | 514,423 | 275,319 | 1,862,083 | — | 11,562 | 3,449,065 |
| Jeffrey P. Castelli | Chief Development Officer | 2024 | 491,807 | 263,494 | 1,862,083 | — | 39,834 | 3,442,896 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 499 |
| 2023 | 517 |
| 2022 | 484 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 528,295,000 | 399,356,000 | 329,233,000 |
| Cost Of Revenue | 52,943,000 | 37,326,000 | 38,599,000 |
| Gross Profit | 475,352,000 | 362,030,000 | 290,634,000 |
| Research And Development Expenses | 109,362,000 | 152,381,000 | 276,677,000 |
| General And Administrative Expenses | 323,379,000 | 275,270,000 | 213,041,000 |
| Operating Expenses | 450,476,000 | 439,241,000 | 502,754,000 |
| Operating Income | 24,876,000 | -77,211,000 | -212,120,000 |
| Net Income | -56,106,000 | -151,584,000 | -236,568,000 |
| Earnings Per Share Basic | -0.18 | -0.51 | -0.82 |
| Earnings Per Share Diluted | -0.18 | -0.51 | -0.82 |
| Weighted Average Shares Outstanding Basic | 304,380,502 | 295,164,515 | 289,057,198 |
| Weighted Average Shares Outstanding Diluted | 304,380,502 | 295,164,515 | 289,057,198 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 213,752,000 | 246,994,000 | 148,813,000 |
| Marketable Securities Current | 36,194,000 | 39,206,000 | 144,782,000 |
| Accounts Receivable | 101,099,000 | 87,632,000 | 66,196,000 |
| Inventories | 118,782,000 | 59,696,000 | 23,816,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 504,736,000 | 483,061,000 | 423,816,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 29,383,000 | 31,667,000 | 30,778,000 |
| Other Assets Non Current | 13,641,000 | 18,553,000 | 19,242,000 |
| Total Assets Non Current | 280,297,000 | 294,819,000 | 300,351,000 |
| Total Assets | 785,033,000 | 777,880,000 | 724,167,000 |
| Accounts Payable | 12,947,000 | 15,120,000 | 15,413,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 148,702,000 | 167,689,000 | 139,018,000 |
| Long Term Debt | 390,111,000 | 387,858,000 | 391,990,000 |
| Other Liabilities Non Current | 7,097,000 | 13,282,000 | 8,939,000 |
| Total Liabilities Non Current | 442,286,000 | 450,017,000 | 462,102,000 |
| Total Liabilities | 590,988,000 | 617,706,000 | 601,120,000 |
| Common Stock | 2,944,000 | 2,918,000 | 2,815,000 |
| Retained Earnings | -2,740,180,000 | -2,684,074,000 | -2,532,490,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 194,045,000 | 160,174,000 | 123,047,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 8,547,000 | 7,873,000 | 5,342,000 |
| Share Based Compensation Expense | 84,905,000 | 86,077,000 | 76,512,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 19,484,000 | 20,108,000 | 17,330,000 |
| Change In Inventories | 73,652,000 | 44,614,000 | 5,343,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -16,520,000 | 49,195,000 | -6,377,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -33,891,000 | -69,091,000 | -166,575,000 |
| Purchases Of Marketable Securities | 114,786,000 | 91,723,000 | 243,255,000 |
| Sales Of Marketable Securities | 117,779,000 | 197,227,000 | 335,926,000 |
| Acquisition Of Property Plant And Equipment | 3,553,000 | 7,440,000 | 3,766,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -560,000 | 98,064,000 | 92,316,000 |
| Tax Withholding For Share Based Compensation | 22,025,000 | 17,920,000 | 11,490,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 0 | 408,043,000 | 0 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 5,121,000 | 61,677,000 | -7,463,000 |
| Change In Cash | -33,361,000 | 96,962,000 | -96,341,000 |
| Cash At End Of Period | 213,752,000 | 246,994,000 | 148,813,000 |
| Income Taxes Paid | 8,214,000 | 8,525,000 | 1,609,000 |
| Interest Paid | 58,960,000 | 36,090,000 | 34,358,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.18 | -0.51 | -0.82 |
| Price To Earnings Ratio | -52.3333 | -27.8235 | -14.8902 |
| Earnings Growth Rate | -64.7059 | -37.8049 | -10.8696 |
| Price Earnings To Growth Ratio | 0.8088 | 0.736 | 1.3699 |
| Book Value Per Share | 0.6375 | 0.5427 | 0.4257 |
| Price To Book Ratio | 14.7763 | 26.149 | 28.6833 |
| Ebitda | 10,253,000 | -85,037,000 | -192,498,000 |
| Enterprise Value | 3,043,623,328.84 | 4,329,248,467.85 | 3,772,565,387.58 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 2.0104 | 2.4215 | 3.1857 |
| Capital Expenditures | 6,263,000 | 8,762,000 | -6,376,000 |
| Free Cash Flow | -40,154,000 | -77,853,000 | -160,199,000 |
| Return On Equity | -0.2891 | -0.9464 | -1.9226 |
| One Year Beta | 1.0205 | 0.8319 | 1.1579 |
| Three Year Beta | 1.0623 | 1.0772 | 1.283 |
| Five Year Beta | 1.2259 | 1.2527 | 1.3172 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Harford Simon N.R. | Chief Financial Officer | 2025-08-21 | 12,529 | D | 214,898 |
| WHEELER CRAIG A | Director | 2025-06-05 | 74,872 | A | 74,872 |
| Bleil Lynn Dorsey | Director | 2025-06-05 | 20,414 | A | 113,941 |
| Bleil Lynn Dorsey | Director | 2025-06-05 | 74,872 | A | 74,872 |
| ROBERTS EIRY | Director | 2025-06-05 | 20,414 | A | 76,275 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Daniel Goldman | 2023-05-19 | NY10 | Sale | 2023-04-10 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| TEACHER RETIREMENT SYSTEM OF TEXAS | 2025-09-30 | 475,479 | 60,340 | 7.88 |
| Parkside Financial Bank & Trust | 2025-09-30 | 2,128 | 270 | 7.8815 |
| Covestor Ltd | 2025-09-30 | 104,000 | 13,227 | 7.8627 |
| CALDWELL SUTTER CAPITAL, INC. | 2025-09-30 | 3,152 | 400 | 7.88 |
| WPG Advisers, LLC | 2025-09-30 | 134 | 17 | 7.8824 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Multi-Asset Real Return Fund - Class A | SEIAX | 2,796 | 21,221.64 | 0.0028 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Extended Market Index Fund - Class A | SMXAX | 37,700 | 286,143 | 0.0236 |
| ALPS ETF Trust | 2025-08-31 | ALPS Medical Breakthroughs ETF | SBIO | 145,707 | 1,105,916.13 | 1.3656 |
| Northern Lights Fund Trust IV | 2025-08-31 | Inspire Small/Mid Cap ETF | ISMD | 69,657 | 528,696.63 | 0.2404 |
| Exchange Place Advisors Trust | 2025-08-31 | CLASS A | ORSAX | 244,650 | 1,856,893.5 | 0.3243 |